Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma

Sorafenib is the first-line medication for advanced hepatocellular carcinoma (HCC), but it can only extend limited survival. It is imperative to find a combination strategy to increase sorafenib efficacy. Artesunate is such a preferred candidate, because artesunate is clinically well-tolerated and m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Acta pharmacologica Sinica 2021-02, Vol.42 (2), p.301-310
Hauptverfasser:	Li, Zhong-jie, Dai, Hui-qi, Huang, Xiao-wei, Feng, Ji, Deng, Jing-huan, Wang, Zi-xuan, Yang, Xiao-mei, Liu, Yu-jia, Wu, Yong, Chen, Pan-hong, Shi, Huan, Wang, Ji-gang, Zhou, Jing, Lu, Guo-dong
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - pharmacology Artesunate Artesunate - administration & dosage Artesunate - pharmacology Biomedical and Life Sciences Biomedicine Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Cathepsin B Cell death Cell Line, Tumor Deferoxamine Drug development Drug Synergism Ferritin Ferroptosis Ferroptosis - drug effects Glutathione Hepatocellular carcinoma Humans Immunology Inhibitor drugs Internal Medicine Lipid peroxidation Lipid Peroxidation - drug effects Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - pathology Male Medical Microbiology Mice Mice, Inbred BALB C Mice, Nude Mitochondria Molecular modelling Oxidative stress Oxidative Stress - drug effects Pharmacology/Toxicology Sorafenib - administration & dosage Sorafenib - pharmacology Targeted cancer therapy Vaccine Xenograft Model Antitumor Assays Xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!